Does GLP-1 suppress its own basal secretion?

Endocrine Research

Volumn 41, Issue 1, 2016, Pages 16-20

  Elahi, Dariush ^a   Ruff, Dennis A ^a   Carlson, Olga D ^b   Meneilly, Graydon S ^c   Habener, Joel F ^d   Egan, Josephine M ^b  

^a Early Phase Services LLC   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

GLP 1; Glucose clamp; Insulin; Negative feedback

Indexed keywords

BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 2; INCRETIN; PEPTIDE YY; UNCLASSIFIED DRUG; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; MALE; NEGATIVE FEEDBACK; OBESITY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BASAL METABOLIC RATE; BLOOD; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGICAL FEEDBACK; SECRETION (PROCESS);

ADULT; BASAL METABOLISM; BLOOD GLUCOSE; FEEDBACK, PHYSIOLOGICAL; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; OBESITY; PEPTIDE FRAGMENTS; PEPTIDES; THINNESS;

EID: 84939536418     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2015.1038353     Document Type: Article

References (26)

1. Elahi D, Hershlopf RJ, Muller DC, et al. Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Eng J Med 1982;308:1196-202 (Regul Pept 1995;58:149-56).
2. Brunicardi FC, Gingerich RL, Andersen DK. Selective effects of arterial insulin on islet cell secretion in the isolated perfused human pancreas. Surg Forum 1990;41:198-200.
3. Drucker D. Glucagon-like peptides. Diabetes 1998;47:159-69.
4. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagonlike peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46.
5. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19.
6. FDA. FDA Approves New Drug Treatment for Type 2 Diabetes. U.S. Department of Health & Human Services, 2009.
7. Kim BJ, Carlson OD, Jang HJ, et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005;90:6665-71.
8. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002;87:3768-73.
9. Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide. Obesity (Silver Spring) 2008;16:1501-9.
10. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-90.
11. Hansen L, Hartmann B, Bisgaard T, et al. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000;278:E1010-18.
12. Marco J, Hedo JA, Villaneuva ML. Inhibition of intestinal glucagon-like immunoreactivity (GLI) secretion by somatostatin in man. J Clin Endocrinol Metab 1977;44:695-8.
13. Martin PA, Faulkner A. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep. J Endocrinol 1996;151:107-12.
14. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-916.
15. Tofit-Nielsen M-B, Masbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-43.
16. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide-1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-14.
17. Standeven KF, Hess K, Carter AM, et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes 2011;35:1031-40.
18. Palmboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005;48:1882-90.
19. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995;58:149-56.
20. Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 2014;16:1155-64.
21. Grigoryan M, Kedees MH, Charron MJ, et al. Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology 2012;153:3.
22. Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93: 4909-16.
23. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagonlike peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95: 215-21.
24. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475-80.
25. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999;140:1687-94.
26. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342-9.